- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Chris Ryan | Authors
Follow-up Data Show Continuous Advantage of Zanubrutinib Over Ibrutinib for MYD88+ Waldenström Macroglobulinemia
June 12, 2022
Follow-up results of the phase 3 ASPEN trial comparing zanubrutinib with ibrutinib in patients with Waldenström macroglobulinemia were presented at 2022 ASCO.
Seribantumab Leads to Promising Efficacy in Solid Tumors with NRG1 Fusions
June 10, 2022
Results from the phase 2 CRESTONE trial showed positive overall response rates in patients with solid tumors harboring NRG1 fusions treated with seribantumab monotherapy.
Adding Frontline Toripalimab to Chemotherapy for NSCLC Across PD-L1 Expression Levels Led to Survival Boost
June 10, 2022
Results of the CHOICE-01 trial demonstrate the utility of toripalimab added to chemotherapy in advanced frontline non–small cell lung cancer at 2022 ASCO.
18F-rhPSMA-7.3 Exhibits Greater Ability to Upstage Disease Vs Conventional Imagine in Recurrent Prostate Cancer
May 16, 2022
Superior post-scan disease upstaging in patients with recurrent prostate cancer was observed with 18F-rhPSMA-7.3 compared with conventional baseline imaging.
CAR T-Cell Products Yield Notable Responses Without Increase in Neurotoxicity or CRS in LBCL With CNS Involvement
April 25, 2022
Treatment with several CAR T-cell products resulted in notable responses without an increase in cytokine release syndrome or neurotoxicity in large B-cell lymphoma with central nervous system involvement.
Advanced Melanoma With Resistance to PD-1 Inhibition May Derive Benefit From BO-112 Plus Pembrolizumab
April 13, 2022
Novel BO-112 when combined with pembrolizumab may offer a new treatment option for patients with advanced melanoma and PD-1 inhibitor therapy resistance.
Ibrutinib Plus Venetoclax at a Fixed Duration Yields Positive PFS in CLL/SLL
April 12, 2022
Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma.
Similar OS Between Olaparib and Chemotherapy Observed in Platinum-Sensitive Ovarian Cancer
March 19, 2022
Olaparib and non-platinum chemotherapy produced similar overall survival results when treating patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations.
Olaparib Investigated After First-Line Chemo in Ovarian Cancer
March 19, 2022
Olaparib maintenance therapy will be investigated after receiving first-line chemotherapy for patients with BRCA1/2 wild-type advanced ovarian cancer.
Data Points to Better Outcomes in mCSPC With ADT-Based Combos Vs ADT Alone
March 17, 2022
At a recent conference, Robert Dreicer, MD, MS, MACP, FASCO, offered his advice regarding the use of androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer.